MTB 9655
Alternative Names: MTB-9655Latest Information Update: 28 Jul 2024
At a glance
- Originator Metabomed
- Class Antineoplastics; Small molecules
- Mechanism of Action ACSS2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Israel (PO, Capsule)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO, Capsule)
- 16 Jan 2024 EpiVario acquires acetyl co-A synthetase-2 inhibitor ("ACSS2i") portfolio including MTB 9655 from Metabomed